Millions of people suffer and die unnecessarily from cancer due to a lack of awareness, resources, and access to affordable, quality healthcare. Let's join forces to change this – #CloseTheCareGap on #WorldCancerDay. MaxCyte advocates for better cancer support worldwide.

#CART cell therapy could be revolutionary in fight against solid tumors. Research suggests it may help prevent recurrence & eliminate residual cancer cells after surgical removal of tumors. This brings us one step closer to more effective treatments.https://www.science.org/doi/10.1126/sciadv.ade2526

While HIV is managed by lifelong ART therapy, the use of gene editing may provide a single dose alternative. Read our app note to learn about the success of CCR5 disruption in HSPC as a treatment for HIV using our non-viral #cellengineering technology. http://ow.ly/7iGs50IKALg

In case you missed it - our Chief Scientific Officer, Cenk Sumen, spoke with @pharmasalmanac about our development process on failing fast and confidently along with #transientexpression, and #electroporation. Read more: https://www.pharmasalmanac.com/articles/overcoming-limitations-with-transient-protein-expression-to-accelerate-development

Have you checked out this insightful interview between @PharmaVoice and MaxCyte President & CEO, Doug Doerfler? Learn about our cutting-edge technology and its many applications in #celltherapy and #CRISPR: https://bit.ly/3rzhwhE

Load More
Millions of people suffer and die unnecessarily from cancer due to a lack of awareness, resources, and access to affordable, quality healthcare. Let's join forces to change this – #CloseTheCareGap on #WorldCancerDay. MaxCyte advocates for better cancer support worldwide. https://t.co/kBZNm2e5Io MaxCyte_info photo
#CART cell therapy could be revolutionary in fight against solid tumors. Research suggests it may help prevent recurrence & eliminate residual cancer cells after surgical removal of tumors. This brings us one step closer to more effective treatments. https://t.co/9MHHGRcmL0
While HIV is managed by lifelong ART therapy, the use of gene editing may provide a single dose alternative. Read our app note to learn about the success of CCR5 disruption in HSPC as a treatment for HIV using our non-viral #cellengineering technology. https://t.co/FQPzrxJ04J https://t.co/5G4bBZZZrV MaxCyte_info photo
In case you missed it - our Chief Scientific Officer, Cenk Sumen, spoke with @pharmasalmanac about our development process on failing fast and confidently along with #transientexpression, and #electroporation. Read more: https://t.co/h1E3pjQllA